Robert P. Lisak

Overview

Best Publications

• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial

  K. P. Johnson;B. R. Brooks;J. A. Cohen;C. C. Ford

  2459
  Citations

• Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture

  Martin C. Raff;Rhona Mirsky;K. L. Fields;Robert P. Lisak

  943
  Citations

• Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

  James F Howard;Kimiaki Utsugisawa;Michael Benatar;Hiroyuki Murai

  844
  Citations

• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  Kenneth P. Johnson;B. R. Brooks;Jeffrey A Cohen;C. C. Ford

  714
  Citations

• Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

  Alexander Rae-Grant;Gregory S. Day;Ruth Ann Marrie;Alejandro Rabinstein

  546
  Citations

• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

  Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  514
  Citations

• Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis

  Bin Zhang;John S. Tzartos;Maria Belimezi;Samia Ragheb

  401
  Citations

• Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.

  G. M. McKhann;J. W. Griffin;David Cornblath;E. D. Mellits

  357
  Citations

• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.

  James F Howard;Vera Bril;Tuan Vu;Chafic Karam

  348
  Citations

• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

  K. P. Johnson;B. R. Brooks;C. C. Ford;A. Goodman

  339
  Citations

• Isolation of myelin basic protein-reactive T-cell lines from normal human blood

  James Burns;Anthony Rosenzweig;Burton Zweiman;Robert P. Lisak

  335
  Citations

• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

  K P Johnson;B R Brooks;C C Ford;A Goodman

  308
  Citations

• Experimental allergic neuritis induced by sensitization with galactocerebroside.

  Takahiko Saida;Kyoko Saida;Susan H. Dorfman;Donald H. Silberberg

  300
  Citations

• Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate:

  C. Ford;AD Goodman;K. Johnson;N. Kachuck

  257
  Citations

• Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies.

  Robert P. Lisak;Madeline Mitchell;Burton Zweiman;Edward Orrechio

  238
  Citations

• Autoantibodies to agrin in myasthenia gravis patients

  Bin Zhang;Chengyong Shen;Beverly Bealmear;Samia Ragheb

  217
  Citations

• Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro

  Robert P. Lisak;Joyce A. Benjamins;Liljana Nedelkoska;Jennifer L. Barger

  212
  Citations

• In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.

  Lisak Rp;Zweiman B

  211
  Citations

• The thymus in myasthenia gravis. Evidence for altered cell populations.

  Nabih I. Abdou;Robert P. Lisak;Burton Zweiman;Ises Abrahamsohn

  210
  Citations

• CELL TYPE-SPECIFIC MARKERS FOR HUMAN GLIAL AND NEURONAL CELLS IN CULTURE

  P. G E Kennedy;R. P. Lisak;M. C. Raff

  195
  Citations

• Chronic cerebrospinal venous insufficiency and multiple sclerosis.

  Omar Khan;Massimo Filippi;Mark S. Freedman;Frederik Barkhof

  189
  Citations

• In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome.

  Takahiko Saida;Kyoko Saida;Robert P. Lisak;Mark J. Brown

  183
  Citations

• Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders

  John N. Whitaker;Robert P. Lisak;Rifaat M. Bashir;Olive H. Fitch

  181
  Citations

• Antibodies to Oligodendroglia in Patients with Multiple Sclerosis

  O. Abramsky;R. P. Lisak;D. H. Silberberg;David E Pleasure

  176
  Citations

• Enrichment of Schwann cell cultures from neonatal rat sciatic nerve by differential adhesion

  B. Q. Kreider;B. Q. Kreider;A. Messing;A. Messing;H. Doan;H. Doan;S. U. Kim;S. U. Kim

  172
  Citations

• Mitogens for glial cells: a comparison of the response of cultured astrocytes, oligodendrocytes and schwann cells

  Rebecca M. Pruss;Perry F. Bartlett;Jelena Gavrilovic;Robert P. Lisak

  164
  Citations

• Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration

  Dusanka S. Skundric;Robert P. Lisak

  142
  Citations

• Antimyelin antibodies in neurologic diseases. Immunofluorescent demonstration.

  Robert P. Lisak;Burton Zwiman;Michael Norman

  134
  Citations

• Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.

  Samia Ragheb;Yanfeng Li;Kirk Simon;Stephen VanHaerents

  134
  Citations